A recently created services arm at drug-discovery firm Galapagos will help Novartis Pharmaceuticals UK develop and conduct functional assays in primary human cells in an undisclosed disease area, the company said this week.

Under the terms of the agreement, the services division, called Galádeno, will use its SilenceSelect gene knockdown platform to design a research program for Novartis. SilenceSelect is based on Galádeno's collection of adenoviruses with human gene sequences that knock down more than 4,000 human proteins by producing siRNA in human cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.